What's New

Last Posted: Jun 05, 2023

• Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
  M Tsuboi et al, NEJM, June 4, 2023
• Benchmarking machine learning approaches to predict radiation-induced toxicities in lung cancer patients.
  Francisco J Núñez-Benjumea et al. Clin Transl Radiat Oncol 2023 41100640
• Adjuvant therapies in stages I-III epidermal growth factor receptor-mutated lung cancer: current and future perspectives.
  Mark G Kris et al. Transl Lung Cancer Res 2023 12(4) 824-836
• Performance of Ultra-Rapid Idylla™ EGFR Mutation Test in Non-Small-Cell Lung Cancer and Its Potential at Clinical Molecular Screening.
  Kenichi Suda et al. Cancers (Basel) 2023 15(9)
• Integration of Radiomics and Tumor Biomarkers in Interpretable Machine Learning Models.
  Lennart Brocki et al. Cancers (Basel) 2023 15(9)
• Adjuvant Treatments for Surgically Resected Non-Small Cell Lung Cancer Harboring EGFR Mutations: A Review.
  Antonio Passaro et al. JAMA Oncol 2023 5
• Validation of lung cancer polygenic risk scores in a high-risk case-control cohort.
  Mikey B Lebrett et al. Genet Med 2023 100882
• Bayesian network enables interpretable and state-of-the-art prediction of immunotherapy responses in cancer patients.
  Hideki Hozumi et al. PNAS Nexus 2023 2(5) pgad133
• Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations.
  Jinfei Si et al. BMC Pulm Med 2023 23(1) 158
• Clinical Outcomes Beyond 1L EGFR-TKI Progression in mNSCLC: Final Results of the Real-World Study 'LUNGFUL'.
  Giannis Mountzios et al. Anticancer Res 2023 43(5) 2243-2258

More